Biofilm and the Breast Implant: Why Capsular Contracture Is Increasingly Treated as an Infection Problem

Ask ten patients what causes capsular contracture, the hardening and distortion that remains the most common reason for reoperation after breast augmentation, and most will say some version of "my body rejected the implant." That framing is understandable but outdated. Over the past two decades, evidence has steadily pointed to a different culprit: subclinical bacterial biofilm, a thin, low-grade colonization of the implant surface that never produces a visible infection but keeps the immune system chronically irritated.

Here is the mechanism in plain terms. Every implant placed in the body becomes surrounded by a capsule of scar tissue. This is normal and expected. A healthy capsule is soft, thin, and unnoticeable. Problems begin when the capsule thickens and tightens, squeezing the implant into a firmer, rounder, sometimes painful shape. Surgeons grade this on the Baker scale, from Grade I, which is a soft and natural result, to Grade IV, which is hard, distorted, and painful.

The biofilm hypothesis holds that contracture is often triggered when a small number of bacteria, most commonly skin and breast duct organisms such as Staphylococcus epidermidis and Cutibacterium acnes, attach to the implant during surgery. These bacteria do not cause redness, fever, or pus. Instead, they secrete a slimy protective matrix and settle into a dormant, low-metabolism state. Inside that matrix, they are largely shielded from antibiotics and immune cells. The immune system cannot clear them, so it does the only thing it can: it walls them off with progressively denser scar tissue. Chronic inflammation drives fibroblasts to lay down collagen and myofibroblasts to contract it. The result, months or years later, is a hard capsule.

Several lines of evidence support this. Laboratory studies have recovered biofilm from contracted capsules at much higher rates than from soft ones. Animal models show that deliberately inoculating implants with small bacterial loads reliably produces contracture. And, most persuasively for practice, surgical protocols designed to reduce contamination have been associated with measurably lower contracture rates in large case series.

This is where the theory becomes practical. Many surgeons now follow a bundle of intraoperative steps, often called the 14-point plan, aimed at minimizing bacterial contact with the implant. The individual steps are simple. The logic behind each is worth understanding if you are researching a procedure.

Pocket irrigation. The surgical pocket is washed with antibiotic or antiseptic solution before the implant goes in, reducing the bacterial load in the space itself.

No-touch or minimal-touch insertion. Some surgeons use an insertion sleeve, a cone-shaped funnel that lets the implant slide into the pocket without contacting the skin. The skin around the nipple and incision is impossible to sterilize completely, so avoiding contact matters. Studies of funnel use have reported reduced contamination in laboratory models.

Nipple shields. The nipple ducts harbor bacteria that cannot be scrubbed away. Occlusive dressings over the nipples during surgery block one contamination route.

Glove changes and fresh instruments. Gloves are changed before handling the implant, and the implant is opened from its packaging only at the moment of insertion, limiting airborne and contact exposure.

Incision choice. This is more debated, but some data suggest that incisions passing near the nipple ducts, such as the periareolar approach, carry higher contracture rates than the inframammary fold incision, plausibly because the dissection traverses duct-bearing tissue. The difference is not enormous, and surgeon experience with a given approach matters, but the mechanism is coherent.

Avoiding drains when feasible. A drain is a highway from the outside world into the pocket. Many surgeons reserve drains for specific indications rather than routine use.

What does this mean for patients weighing risk? First, contracture is not fully preventable. Published rates vary widely, roughly 2 to 15 percent over ten years depending on implant type, placement, and technique, and some cases occur despite meticulous protocol. Hematoma, radiation exposure, and genetic tendencies toward aggressive scarring also contribute, so biofilm is the dominant theory, not the only pathway. Second, placement matters: submuscular positioning is consistently associated with lower contracture rates than subglandular placement, possibly because muscle motion and better tissue coverage alter the local environment. Third, if contracture does develop, established treatment usually means surgery: removing the capsule partially or completely, exchanging the implant, and often changing the pocket plane. Massage, ultrasound, and off-label medications have weak or mixed evidence, and a biofilm that has matured on an implant surface generally cannot be eradicated without removing the surface it lives on.

The practical takeaway is a question worth asking in any consultation: what specific steps do you take to reduce implant contamination during surgery? A surgeon who can walk through their protocol, irrigation solution, insertion technique, incision rationale, is demonstrating engagement with the best current understanding of why implants harden. The answer will tell you more about their standards than any before-and-after photo.

Related reading: Breast Implant Illness: What the Symptoms and the Evidence Actually Say.

Further reading: Role of biofilms in breast implant associated infections and capsular contracture (Adv Exp Med Biol 2015); A Meta-analysis of Breast Implant Irrigation Solutions' Effect on Infection and Capsular Contracture Frequencies (Ann Plast Surg 2025); The A, B and C's of Silicone Breast Implants: Anaplastic Large Cell Lymphoma, Biofilm and Capsular Contracture (Materials (Basel) 2018).